Boundless Bio Raises Oversubscribed $105 Million Series B Financing To Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal Dna (Ecdna)

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced the closing of an oversubscribed $105 Million Series B financing. With the proceeds of the financing, the company will advance into the clinic multiple ecDNA-directed therapeutic programs and the accompanying ecDNA Harboring Oncogenes (ECHOTM) companion diagnostic and expand its pipeline of novel cancer therapies targeting ecDNA.